Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer

Hideki Katayama, H. Ueoka, Katsuyuki Kiura, Masahiro Tabata, T. Kozuki, M. Tanimoto, Toshiyoshi Fujiwara, N. Tanaka, H. Date, M. Aoe, N. Shimizu, M. Takemoto, Y. Hiraki

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated with induction chemoradiotherapy consisting of cisplatin (40 mg m-2) and docetaxel (40 mg m-2) given on days 1, 8, 29 and 36 plus concurrent thoracic irradiation at a dose of 40-60 Gy (2 Gy fraction-1 day-1). Surgical resection was performed within 6 weeks after completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73%). In all, 20 patients (91%) underwent surgery and complete resection was achieved in 19 patients (86%). Pathological downstaging and pathological complete response were obtained in 14 (6496) and five (23%) patients, respectively. With a median follow-up period of 32 months, the calculated 3-year overall and progression-free survival rates were 66 and 61%, respectively. It is noteworthy that the 3-year overall survival rate in 14 patients achieving pathological downstaging was extremely high (93%). Toxicity was manageable with standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.

Original languageEnglish
Pages (from-to)979-984
Number of pages6
JournalBritish Journal of Cancer
Volume90
Issue number5
DOIs
Publication statusPublished - Mar 8 2004

Fingerprint

docetaxel
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Cisplatin
Survival Rate
Therapeutics
Disease-Free Survival

Keywords

  • Cisplatin
  • Docetaxel
  • Induction chemoradiotherapy
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. / Katayama, Hideki; Ueoka, H.; Kiura, Katsuyuki; Tabata, Masahiro; Kozuki, T.; Tanimoto, M.; Fujiwara, Toshiyoshi; Tanaka, N.; Date, H.; Aoe, M.; Shimizu, N.; Takemoto, M.; Hiraki, Y.

In: British Journal of Cancer, Vol. 90, No. 5, 08.03.2004, p. 979-984.

Research output: Contribution to journalArticle

Katayama, Hideki ; Ueoka, H. ; Kiura, Katsuyuki ; Tabata, Masahiro ; Kozuki, T. ; Tanimoto, M. ; Fujiwara, Toshiyoshi ; Tanaka, N. ; Date, H. ; Aoe, M. ; Shimizu, N. ; Takemoto, M. ; Hiraki, Y. / Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. In: British Journal of Cancer. 2004 ; Vol. 90, No. 5. pp. 979-984.
@article{2335c8d9499742718a7630503f8c5ded,
title = "Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer",
abstract = "The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated with induction chemoradiotherapy consisting of cisplatin (40 mg m-2) and docetaxel (40 mg m-2) given on days 1, 8, 29 and 36 plus concurrent thoracic irradiation at a dose of 40-60 Gy (2 Gy fraction-1 day-1). Surgical resection was performed within 6 weeks after completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73{\%}). In all, 20 patients (91{\%}) underwent surgery and complete resection was achieved in 19 patients (86{\%}). Pathological downstaging and pathological complete response were obtained in 14 (6496) and five (23{\%}) patients, respectively. With a median follow-up period of 32 months, the calculated 3-year overall and progression-free survival rates were 66 and 61{\%}, respectively. It is noteworthy that the 3-year overall survival rate in 14 patients achieving pathological downstaging was extremely high (93{\%}). Toxicity was manageable with standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.",
keywords = "Cisplatin, Docetaxel, Induction chemoradiotherapy, Non-small-cell lung cancer",
author = "Hideki Katayama and H. Ueoka and Katsuyuki Kiura and Masahiro Tabata and T. Kozuki and M. Tanimoto and Toshiyoshi Fujiwara and N. Tanaka and H. Date and M. Aoe and N. Shimizu and M. Takemoto and Y. Hiraki",
year = "2004",
month = "3",
day = "8",
doi = "10.1038/sj.bjc.6601624",
language = "English",
volume = "90",
pages = "979--984",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer

AU - Katayama, Hideki

AU - Ueoka, H.

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Kozuki, T.

AU - Tanimoto, M.

AU - Fujiwara, Toshiyoshi

AU - Tanaka, N.

AU - Date, H.

AU - Aoe, M.

AU - Shimizu, N.

AU - Takemoto, M.

AU - Hiraki, Y.

PY - 2004/3/8

Y1 - 2004/3/8

N2 - The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated with induction chemoradiotherapy consisting of cisplatin (40 mg m-2) and docetaxel (40 mg m-2) given on days 1, 8, 29 and 36 plus concurrent thoracic irradiation at a dose of 40-60 Gy (2 Gy fraction-1 day-1). Surgical resection was performed within 6 weeks after completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73%). In all, 20 patients (91%) underwent surgery and complete resection was achieved in 19 patients (86%). Pathological downstaging and pathological complete response were obtained in 14 (6496) and five (23%) patients, respectively. With a median follow-up period of 32 months, the calculated 3-year overall and progression-free survival rates were 66 and 61%, respectively. It is noteworthy that the 3-year overall survival rate in 14 patients achieving pathological downstaging was extremely high (93%). Toxicity was manageable with standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.

AB - The objective of this study was to assess the feasibility and effectiveness of an induction chemoradiotherapy regimen followed by surgery in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). A total of 22 patients with LA-NSCLC were treated with induction chemoradiotherapy consisting of cisplatin (40 mg m-2) and docetaxel (40 mg m-2) given on days 1, 8, 29 and 36 plus concurrent thoracic irradiation at a dose of 40-60 Gy (2 Gy fraction-1 day-1). Surgical resection was performed within 6 weeks after completion of induction therapy. Objective response to the induction therapy was obtained in 16 patients (73%). In all, 20 patients (91%) underwent surgery and complete resection was achieved in 19 patients (86%). Pathological downstaging and pathological complete response were obtained in 14 (6496) and five (23%) patients, respectively. With a median follow-up period of 32 months, the calculated 3-year overall and progression-free survival rates were 66 and 61%, respectively. It is noteworthy that the 3-year overall survival rate in 14 patients achieving pathological downstaging was extremely high (93%). Toxicity was manageable with standard approaches. No treatment-related deaths occurred. This combined modality treatment is feasible and highly effective in patients with LA-NSCLC. The results warrant further large-scale study to confirm the effectiveness of this regimen.

KW - Cisplatin

KW - Docetaxel

KW - Induction chemoradiotherapy

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=11144356398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144356398&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601624

DO - 10.1038/sj.bjc.6601624

M3 - Article

VL - 90

SP - 979

EP - 984

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -